Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA Margin: 2009-2019

Historic EBITDA Margin for Neurocrine Biosciences (NBIX) over the last 10 years, with Dec 2019 value amounting to 5.12%.

  • Neurocrine Biosciences' EBITDA Margin rose 3032.00% to 7.50% in Q3 2021 from the same period last year, while for Sep 2021 it was 3.41%, marking a year-over-year decrease of 570.00%. This contributed to the annual value of 5.12% for FY2019, which is 46.00% up from last year.
  • As of FY2019, Neurocrine Biosciences' EBITDA Margin stood at 5.12%, which was up 9.87% from 4.66% recorded in FY2018.
  • In the past 5 years, Neurocrine Biosciences' EBITDA Margin ranged from a high of 5.12% in FY2019 and a low of -960.49% during FY2017.
  • Over the past 3 years, Neurocrine Biosciences' median EBITDA Margin value was 4.66% (recorded in 2018), while the average stood at -316.90%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by 48,353bps in 2016, then surged by 96,515bps in 2018.
  • Yearly analysis of 5 years shows Neurocrine Biosciences' EBITDA Margin stood at -452.67% in 2015, then slumped by 48,353bps to -936.21% in 2016, then crashed by 2,429bps to -960.49% in 2017, then soared by 96,515bps to 4.66% in 2018, then soared by 46bps to 5.12% in 2019.